Study Group: Infectious Disease Specialists (EU)(?)
Council Members in this Study Group: 342
Request a survey with this Study Group
Related Study Groups
| Study Group Name | Members |
|---|---|
| HIV Specialists (EU) | 115 |
| Infectious Disease Physicians (UK) | 70 |
| Physicians (Germany) | 1146 |
| Prescribers of Combivir : HIV Specialists (EU) | 15 |
| Certified Medical Microbiologists (US) | 110 |
| Physicians who Treat HCV (EU) | 29 |
| Emergency Medicine Physicians (EU) | 238 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
After the extensive studies published (Mallal et al), it becomes mandatory to perform a genetic HLA screening before starting abacavir-containing antiretroviral associations. Problems are recognizable in these points: - laboratories are not capable to front an exaggerated request of HLA typing; - ad-hoc...
Etravirine is a novel and very promising NNRTI since it has not cross-resistance with the existing NNRTIs (efavirenz and nevirapine), and also encompasses excellent efficacy, convenience, and a good tolerability.
HIV therapy must be the strongest and the most safe therapy ; NNRTI are the key drugs for this kind of therapy. When you,doctor,begin a naive HIV therapy, you must think that your patient should be treated for a very long time , maybe for a whole life period ; it'simportant...
Atripla is a fixed combination in a single pill of three excellent antiretroviral drugs with very good pharmacokinetics profile and fairly good tolerability. It will have a considerable impact on compliance as it can be taken once daily. If compliance will be as good as predictable, the chances that...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Professor
- Director
- Physician - Department Chair
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

